SOURCE: The Bedford Report

The Bedford Report

November 04, 2011 08:16 ET

Cancer Treatments From Dendreon and Cell Therapeutics May Not Be as Lucrative as Hoped

The Bedford Report Provides Equity Research on Dendreon & Cell Therapeutics

NEW YORK, NY--(Marketwire - Nov 4, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation and shockingly disappointing earnings elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on Dendreon Corporation (NASDAQ: DNDN) and Cell Therapeutics, Inc. (NASDAQ: CTIC). Access to the full company reports can be found at:

www.bedfordreport.com/DNDN

www.bedfordreport.com/CTIC

This earnings season has been cruel to the biotech industry. Dendreon's announcement that sales of its revolutionary prostate cancer drug, Provenge, have come in significantly below expectations for the year has caused a downward push for the entire sector, as investors abandon shares of firms nearing the launch of other highly anticipated drugs.

On the upside for the industry, analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill its pipeline, which has been a net positive for small biotech companies.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Dendreon said that third-quarter revenue from Provenge tripled, but it reported a larger loss than a year ago. The company once expected sales of Provenge to reach $350 million to $400 million in 2011. In August, it withdrew that forecast, saying it expects much slower growth and said concerns about government reimbursement are hurting sales. In response to the disappointing sales, the company said in September that it would eliminate 500 jobs, or more than 25 percent of its work force, to help reduce costs.

Last week Cell Therapeutics Inc. reported a bigger third-quarter loss, and said it has filed a new request for marketing approval of its lymphoma drug pixantrone. Cell Therapeutics' research and development costs rose to $7.5 million from $5.1 million.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information